Over the past few years Dimerix (ASX:DXB) has established all the building blocks in place to commercialise DMX-200 (known in some markets as Qytovra). DXB has gathered extensive clinical data, signed 4 commercial arrangements which provide not just paths to market but also validation and sources of non-dilutive funding in signature and milestone payments (up […]